HIV Viral Suppression With Unintentional Lenacapavir Monotherapy in Adherence-Challenged Patients: A Case Series
Lenacapavir, a long-acting human immunodeficiency virus (HIV) capsid inhibitor, is thought to have a low resistance barrier based on current, limited data. We describe 4 patients experiencing homelessness with severe mental illness who maintained HIV suppression (<30 copies/mL) despite unintentional receipt of lenacapavir monotherapy for 9-38 weeks, highlighting its potential among adherence-challenged populations.
Authors
- Nicky J. Mehtani (ORCID: https://orcid.org/0000-0003-4277-6889)
- Sarah Strieff
- Janet R. Grochowski (ORCID: https://orcid.org/0000-0002-9816-7073)
- Monica Gandhi (ORCID: https://orcid.org/0000-0001-6674-5388)
- Alix Strough
- Anthonia Chimezie
Institutions
- University of California, San Francisco (US)
- San Francisco Department of Public Health (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-05-31
- DOI
- https://doi.org/10.1093/ofid/ofaf330
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Allergy and Infectious Diseases
- National Center for Advancing Translational Sciences